Video

Dr. Chau on the Tolerability of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

Author(s):

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

In a phase I study of the combination of ramucirumab plus pembrolizumab in patients with treatment-naïve gastric or GEJ adenocarcinoma, safety and anti-tumor activity were evaluated. Ramucirumab was administered at 8 mg/kg on days 1 and 8, and pembrolizumab at 200 mg on day 1 of week 3. PD-L1 status was assessed by DAKO PD-L1 22C3 IHC pharmDx assay.

Of 28 patients, 7 achieved an objective response, 6 that were positive for PD-L1 and 1 that was not. Additionally, median progression-free survival was 5.3 months (95% CI 3.2-1.1). At the time of data presentation at the 2018 Gastrointestinal Cancers Symposium, median overall survival had not been reached.

This combination is very well tolerated, says Chau, with very few grade 3/4 toxicities, with the most common grade 3 toxicity being hypertension. Compared to standard cytotoxic chemotherapy where there is a high rate of grade 3/4 side effects, this is a well-tolerated combination for the treatment of patients with gastric or GEJ cancer, Chau concludes. This trial is currently ongoing.

Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School